Editions and corrections
What changed
Regulatory statuses move, trials publish, and editions get corrected. This log records every change to a guide after it was first published, newest first.
October 2026
- October 1, 2026
October review: CJC-1295 and ipamorelin status corrected; Latest updated
Correction: the CJC-1295 / Ipamorelin guide and the field guide said both peptides remain on FDA's Category 2 list. FDA's current list shows both nominations withdrawn by their sponsors, with ipamorelin still in Category 2 for outsourcing facilities only; AOD-9604's entry is corrected the same way. The practical answer is unchanged: neither is nominated, listed, or under review, so pharmacies may not compound them. The BPC-157 / TB-500 price line for a 10 + 10 mg vial is now $60 to $150 (was $120 to $195). Latest sections gained the full TRIUMPH-2 results, FDA's Empower Pharmacy warning letter on compounded GLP-1 blends, the UCLA review of recovery peptides, and NPR's report on GHK-Cu injections.
CJC-1295 / Ipamorelin →
September 2026
- September 23, 2026
Semax, first edition; the editorial standards page
Semax becomes the eighteenth title: the ACTH-fragment nasal drops registered in Russia, what the Russian label says and doses, the human record study by study (open, unblinded, mostly by the inventors; no randomized trial anywhere), the rat BDNF mechanism, the standard dosing block (10 mg vial, 2 mL, 5,000 mcg/mL, with drops and sprays converted), FDA staff's five objections from the May 2026 briefing and the 8 to 5 committee vote in July, safety including the single 2025 adverse event report, and a checklist. Fifteen references. A new page, How we write these, sets out the sourcing and writing rules every guide follows and states that no clinician has yet reviewed an edition.
Semax → - September 23, 2026
KLOW, first edition; GHK-Cu repriced; printed covers redrawn
KLOW becomes its own title, the seventeenth: the four-peptide vial with KPV's record set out in full (two 2008 mouse colitis studies, cell work, no human trial by any route), the standard dosing block (80 mg, 3 mL, 26.7 mg/mL, 10 units, 30 doses), per-ingredient arithmetic, the July 2026 vote on three of its four ingredients, and a checklist. The GHK-Cu guide's price is now $75, in line with the vial. Printed trifold covers now match the web catalog: each family's photograph tinted in its color under the title's own chart lines; all seventeen PDFs re-rendered.
KLOW → - September 23, 2026
September review: a Latest section on every title, prices rechecked, two corrections
Every catalog title now ends with a dated, sourced Latest list of developments since its edition (the August 24 FDA warning letters to five research-vial vendors, the July advisory-committee tallies and the rulemaking that has not followed, the Bronx NAD+ infusion death, Mounjaro's cardiovascular approval, Canada's third semaglutide generic, the TGA's Melanotan II findings, and more). Prices as sold were rechecked against current listings and revised where they had drifted (NAD+, MOTS-c, epitalon, tesamorelin ownership, the BPC-157 / TB-500 blend, KLOW). Corrections: the epitalon guide said the telomerase result had never been replicated outside the Khavinson institute; a Brunel University group repeated it in cell lines in September 2025 and also saw telomere lengthening in breast cancer cells, and the guide now says so. The PT-141 guide said the men's program was abandoned; the developer dropped the stand-alone drug and announced a combination program in 2024 that has reported nothing since.
- September 19, 2026
GLOW: KLOW dosing added, KPV figure corrected
The GLOW guide now carries a full dosing block for the 80 mg KLOW vial: 3 mL of water, 26.7 mg/mL, 10 units daily (2.67 mg of blend), 30 doses a vial. At the same water volume the three GLOW ingredients come out at identical amounts and KPV adds 333 mcg per dose. Correction: the per-dose KPV figure previously read 312 mcg, which assumed a 2.5 mg blend dose; at 3 mL it is 333 mcg. A KLOW draw table was added to the arithmetic section and a KLOW line to the trifold.
GLOW → - September 17, 2026
Epitalon, first edition
The pineal tetrapeptide as a sixteenth title: the Khavinson institute's cell, mouse, and elderly-cohort work and why none of it has been replicated, the absence of any sleep study behind the insomnia nomination, seller courses with the standard dosing block (10 mg vial, 1 mL, 10 mg/mL), the July 2026 advisory vote against FDA staff's recommendation, the telomerase question, and a checklist. Web guide and trifold.
Epitalon → - September 17, 2026
MOTS-c, first edition
The mitochondrial peptide as a fifteenth title: the mouse record, the exercise observation in people, the CB4211 analog trial and its abandonment, the absence of any human trial of MOTS-c itself, seller protocols with the standard dosing block (10 mg vial, 1 mL, 10 mg/mL), the July 2026 advisory vote against FDA staff's recommendation, and a checklist. Web guide and trifold.
MOTS-c → - September 17, 2026
NAD+, first edition
The first non-peptide title: what the coenzyme does, the human evidence by route (oral precursors well studied for the blood level, one placebo-controlled infusion pilot, no injection trial, no functional outcome anywhere), the drip and the shot as sold with the standard dosing block (500 mg vial, 2.5 mL, 200 mg/mL), the 503A interim-policy position and the January 2026 503B warning letter, dose arithmetic across pharmacy concentrations, the rate-dependent infusion effects, and a checklist. Web guide and trifold.
NAD+ → - September 17, 2026
Semaglutide, first edition
The drug in Ozempic and Wegovy as a thirteenth title: the four products and their approvals through the December 2025 pill, the STEP, SELECT, FLOW, and OASIS trials, the label escalation with the standard dosing block (10 mg vial, 2 mL, 5 mg/mL), the 2022 to 2025 shortage era and the 2026 enforcement that ended compounding, the salt-form problem, the label's warnings, and a checklist. Web guide and trifold.
Semaglutide → - September 17, 2026
PT-141, first edition
Bremelanotide as a twelfth title: the approved use in women and its modest effect, the abandoned men's program and why it stopped, doses on the label and as sold with the standard dosing block (10 mg vial, 2 mL, 5 mg/mL; the label dose is 35 units), the three routes to the drug, and the label's blood-pressure, nausea, and pigmentation warnings. Web guide and trifold.
PT-141 → - September 17, 2026
Cagrilintide / Semaglutide, first edition
CagriSema as an eleventh title: what each half is, the REDEFINE trials including the February 2026 loss to tirzepatide, the trial escalation expressed for the 5 + 5 mg blend vial as sold (2 mL, 5 mg/mL, each peptide half the blend figure), each half's regulatory position and why approval would not reach the vial, and safety. Web guide and trifold.
Cagrilintide / Semaglutide → - September 17, 2026
Melanotan II, first edition
The tanning peptide as a tenth title, written as the risks title: the two small Arizona studies that showed it tans, the case reports (moles, melanoma, rhabdomyolysis, renal infarction, priapism, mouth pigmentation), the seller protocol with the standard dosing block (10 mg vial, 2 mL, 5,000 mcg/mL), why nasal sprays cannot be dosed after Australia's August 2026 tests, and why there is no lawful version. Web guide and trifold.
Melanotan II → - September 17, 2026
BPC-157 / TB-500, first edition
The healing blend vendors call the Wolverine stack as a ninth title: what is in the vial, each peptide's human record (three uncontrolled reports for one, none for the other), why the division of labor is a sales story, the vendor protocol with the standard dosing block (20 mg vial, 2 mL, 10 mg/mL, 6 to 10 units) and per-peptide arithmetic, the shared regulatory timeline through the July 2026 votes, and safety. Web guide and trifold.
BPC-157 / TB-500 → - September 16, 2026
GLOW, first edition
The three-peptide blend vial as an eighth title: what is in it and in what proportions, each ingredient's evidence, the three tests a rational combination would pass, the vendor protocol with per-ingredient arithmetic (70 mg vial, 3 mL, 23.3 mg/mL, 10 units), each ingredient's FDA status after the April and July 2026 changes and why the blend has no pathway regardless, and safety as the sum of three unknowns. KLOW covered inside. Web guide and trifold.
GLOW → - September 15, 2026
GHK-Cu, first edition
The copper peptide as a seventh title and the first beauty title: the topical studies and what they support, the injection and its absence of any human trial, FDA's safety statement and the April 2026 list change, protocols for serums and vials with the standard dosing block (50 mg vial, 2.5 mL, 20 mg/mL) and the copper arithmetic, the blend-vial problem, and a checklist. Web guide and trifold.
GHK-Cu → - September 15, 2026
Privacy policy: contact requests
The sign-in page now has a form for prospective members to ask for an introduction. The privacy policy describes what that form collects, that it is used only to reach out about membership, and how long it is kept.
- September 15, 2026
Sermorelin, first edition
The clinic classic as a sixth title: the Geref history, why the 2008 withdrawal left it compoundable, the three 1990s adult trials and what they did and did not measure, protocols on the old label and in clinics with the standard dosing block (5 mg vial, 2 mL, 2,500 mcg/mL), the three routes to the drug, and the label's safety record. Web guide and trifold.
Sermorelin → - September 15, 2026
Tesamorelin, first edition
The only approved growth hormone releaser as a fifth title: the label and its limits, the two Phase 3 trials, every off-label randomized trial, the three routes to the drug and which are lawful, and the milligram dose arithmetic for a 10 mg vial. Web guide and trifold.
Tesamorelin → - September 15, 2026
CJC-1295 / Ipamorelin, first edition
The growth hormone stack as a fourth title: what each half is, the four human studies, the blend-vial dose arithmetic, and why both peptides stay on FDA's do-not-compound list after the 2026 updates. Web guide and trifold.
CJC-1295 / Ipamorelin → - September 9, 2026
Legal pages
Terms of service, privacy policy, and disclaimer published.
- September 9, 2026
Three free reference guides
Reading a Certificate of Analysis, Reconstitution and Injection, and Living with a GLP-1 published as web guides with trifold editions.
- September 9, 2026
Field guide: stacks chapter
Fifteen vendor bundles reviewed against a four-part test; the blend-vial problem explained.
The Peptide Field Guide → - September 9, 2026
The Peptide Field Guide, first edition
Twenty-four peptides graded by evidence with regulatory status and doses as used. Statuses reflect FDA's April 2026 Category 2 update and the July 2026 advisory committee votes; rulemaking on the six recommended peptides is pending.
The Peptide Field Guide → - September 8, 2026
First editions: tirzepatide, retatrutide, BPC-157
The first three catalog titles published. Retatrutide status: not approved, not compoundable, filing planned for 2027. BPC-157 status: removed from Category 2 in April 2026, recommended for listing in July 2026, not yet listed.